4.5 Article

Inhibition of aflatoxin B1 mutagenicity by cyclopiazonic acid in the presence of human liver preparations

Journal

TOXICOLOGY LETTERS
Volume 143, Issue 3, Pages 291-299

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/S0378-4274(03)00196-6

Keywords

cyclopiazonic acid; aflatoxin B-1; mutagenicity; cytochrome P450

Categories

Ask authors/readers for more resources

Co-occurrence of cyclopiazonic acid (CPA) and aflatoxin B-1 (AFB(1)) has been reported in different food commodities. Recently, we have shown that CPA reduces AFB(1) mutagenicity in the standard Salmonella-Microsome-Assay using rat S9-mix for metabolic activation (Environ. Toxicol. Pharmacol. 11 (2002) 207). When using S9-mix prepared from individual liver fractions of human patients, CPA was found to be non-mutagenic, but exerted a significant reduction of the mutagenicity of AFB(1). Moreover, CPA was shown to inhibit testosterone hydroxylation, but not methoxyresorufin dealkylation (MROD), in human S9. Thus, the reduction of the AFB(1) mutagenicity by CPA may be attributed to the inhibitory effect of CPA on cytochrome P450 (CYP450) 3A4 activity. These findings might be of relevance to the epidemiology of food-borne mycotoxicosis as similar molar ratios to those investigated here have been reported in food commodities. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available